about
Required time delay from 99mTc-HMPAO injection to SPECT data acquisition: healthy subjects and patients with rCBF pattern.In vivo proton MR spectroscopy of the breast using the total choline peak integral as a marker of malignancy.PET/MR in oncology: an introduction with focus on MR and future perspectives for hybrid imaging.[123I]FP-CIT ENC-DAT normal database: the impact of the reconstruction and quantification methods.Improving quantitative dosimetry in (177)Lu-DOTATATE SPECT by energy window-based scatter corrections.Intravenous contrast-enhanced CT can be used for CT-based attenuation correction in clinical (111)In-octreotide SPECT/CT.TSPO Imaging in Glioblastoma Multiforme: A Direct Comparison Between 123I-CLINDE SPECT, 18F-FET PET, and Gadolinium-Enhanced MR Imaging.Comment on: 'A Poisson resampling method for simulating reduced counts in nuclear medicine images'.Experimental determination of the weighting factor for the energy window subtraction-based downscatter correction for I-123 in brain SPECT studies.In vivo quantification of cerebral translocator protein binding in humans using 6-chloro-2-(4'-123I-iodophenyl)-3-(N,N-diethyl)-imidazo[1,2-a]pyridine-3-acetamide SPECT.MRI-guided region-of-interest delineation is comparable to manual delineation in dopamine transporter SPECT quantification in patients: a reproducibility study.Proposal for the standardisation of multi-centre trials in nuclear medicine imaging: prerequisites for a European 123I-FP-CIT SPECT database.Calibration of gamma camera systems for a multicentre European ¹²³I-FP-CIT SPECT normal database.Motion correction of single-voxel spectroscopy by independent component analysis applied to spectra from nonanesthetized pediatric subjects.Evaluation of the Serotonin Transporter Ligand 123I-ADAM for SPECT Studies on Humans.Reproducibility of [123I]PE2I binding to dopamine transporters with SPECT.A comparison of different energy window subtraction methods to correct for scatter and downscatter in I-123 SPECT imaging.Validation of a method for accurate and highly reproducible quantification of brain dopamine transporter SPECT studies.
P50
Q33342277-6E7704F6-BDCD-496D-8090-5CE8AA848A0FQ33449145-44BD4C33-98B8-4A5D-91E3-09A6A3BB88E9Q36357752-8861CE79-88C0-431C-A4E9-472F28DC419EQ37610763-53B3D20F-1827-4829-8584-2E3344C54810Q38551420-9AA1FCFC-0EEE-4F5D-A03C-AC46E3878D2AQ40392465-1FF32598-EED5-4EE4-8A4E-126202EB9431Q40727961-A2B28714-0010-420A-90F5-4273BA56C0F3Q40765783-9E7B4C21-9174-42AE-AD80-00E5F8EC7420Q41666335-85FD7863-325A-49FD-BE15-A82888415981Q41751585-3AD054EF-259B-4264-94A7-8CACDC96E2EAQ43059594-90F9FDCA-8360-4DCC-98A4-7237F87609D9Q44129905-116BF638-A111-4A9E-A954-5FBB7AA8A2B7Q45146077-CFD14916-AEAE-4BF3-98A8-7DEF7102248AQ45357443-6A2DE976-982F-47BB-A590-DBE74B5B3408Q46805025-A2C433B0-036C-47B2-9D3E-F5F3D4D7CDCFQ48451949-B0649C69-7A73-469F-8F9B-6FC73E1234E7Q49160272-7FC59658-1727-4126-BDD8-E2D16C4F6980Q51501119-AB4C7C33-F919-4C08-B29A-3C4601D7701F
P50
description
hulumtues
@sq
researcher
@en
հետազոտող
@hy
name
Robin de Nijs
@ast
Robin de Nijs
@da
Robin de Nijs
@de
Robin de Nijs
@en
Robin de Nijs
@es
Robin de Nijs
@fo
Robin de Nijs
@fr
Robin de Nijs
@is
Robin de Nijs
@kl
Robin de Nijs
@nb
type
label
Robin de Nijs
@ast
Robin de Nijs
@da
Robin de Nijs
@de
Robin de Nijs
@en
Robin de Nijs
@es
Robin de Nijs
@fo
Robin de Nijs
@fr
Robin de Nijs
@is
Robin de Nijs
@kl
Robin de Nijs
@nb
prefLabel
Robin de Nijs
@ast
Robin de Nijs
@da
Robin de Nijs
@de
Robin de Nijs
@en
Robin de Nijs
@es
Robin de Nijs
@fo
Robin de Nijs
@fr
Robin de Nijs
@is
Robin de Nijs
@kl
Robin de Nijs
@nb
P1416
P184
P1960
gBHbGP4AAAAJ